Utah Medical Products, Inc. (UTMD) SEC Filings & Earnings Calls

Customer concentration risk: loss of two largest customers (PendoTECH and China BPM distributor) causing significant revenue decline.

“lack of any 2026 sales to UTMD’s two previously largest customers, PendoTECH... and UTMD’s distributor of disposable blood pressure monitoring (BPM) transducer kits in China.” · word for word

Accelerated decline in Filshie Clip System sales, a key product line.

“accelerated decline in worldwide sales of the Filshie Clip System in 3Q 2026, which were $805 (32.7%) lower than in 3Q 2025.”

Slower-than-expected growth in new biopharm customer sales.

“the 2026 growth in new biopharm sales has been slower than expected.” · word for word

Integration risk: moving Orion operations into Femcare facilities may cause disruption.

“The ORION business operations will be moved into Femcare’s existing facilities in Romsey as soon as practical after a transition period.” · word for word

Non-synergistic product line may limit cross-selling benefits.

“Although the devices are not synergistic from a medical use perspective with UTMD’s other devices” · word for word

Customer concentration risk

“The lower sales in comparison with the prior year’s periods were primarily the result of a lack of sales to UTMD’s two previously largest customers, representing a combined $1,065 loss in 2Q 2025 sales, which was 75% of the 2Q decline;” · word for word

Litigation cost risk

“Higher 2Q litigation expenses resulted from the conclusion of expert witness fees not previously estimated, which fees should not continue into 2H 2026.” · word for word

Tariff risk

“The tariffs were $156 in 1H 2026 and $48 in 2Q 2026, compared to zero in 1H 2025” · word for word

New product sales execution risk

“Sales to other biopharma new customers were just $211 in 1H 2026, a slower than expected gain.” · word for word

Customer concentration risk: loss of two largest customers (PendoTECH and China distributor) drove 75% of revenue decline.

“Combined sales to those two entities were zero in 2Q 2026 vs $1,066K in 2Q 2025.”

Litigation cost pressure: higher U.S. litigation costs impacting operating income.

“$213 higher 2Q 2026 U.S. litigation costs compared to 2Q 2025.” · word for word

China Distributor Loss

“Sales to UTMD’s former distributor in China which were $789 in 1Q 2025 (and zero in 1Q 2026), which explains 82% of the $965 lower OUS sales.” · word for word

Litigation Expense Volatility

“litigation expense in 1Q 2026 was $127 higher than in 1Q 2025” · word for word

U.S. Trade Policy Impact on OUS Business

“regain OUS business which has been hindered by recent U.S. government trade policies” · word for word

Employee Health Care Cost Spike

“U.S. G&A heath care costs were $147 higher in 1Q 2026 than in 1Q 2025.” · word for word

Revenue decline driven by loss of key customers in China and OEM segment, plus lower international Filshie Clip sales.

“No sales to previous largest distributor in China or OEM customer PendoTECH; combined lost sales $857K.”

Operating margin pressure from higher litigation and healthcare costs.

“Litigation expenses up $127K, employee healthcare costs up $147K.”

Earnings Decline

“the Company’s consolidated Earnings Before Tax (and MB accrual) in 2025 which were 16% lower than in 2024.” · word for word

Stock Price Underperformance

“Closing market price of UTMD stock per share (end of year) $ 84.22 $61.47 $ 55.96” · word for word

Customer concentration risk

“UTMD’s previously largest OEM customer, PendoTECH, to which sales peaked at $11.6 million in 2022, representing 22% of UTMD’s total consolidated sales in that year, were just 1% ($0.4 million) of total sales in 2025.” · word for word

Litigation risk

“a clip migration product liability lawsuit was filed in TX. Subsequently, the same law firm solicited and recruited complainants in other states, filing cases around the country.” · word for word

Foreign exchange risk

“72% of 2025 OUS sales were invoiced in foreign currencies. Therefore, changes in foreign currency exchange (FX) rates can have a significant impact on UTMD’s USD-reported financial results.” · word for word

Tariff risk

“Foreign currency fluctuations and reciprocal tariffs implemented in 2025 also can have an impact on UTMD’s ability to be cost-competitive with foreign manufacturers.” · word for word

Product concentration risk

“In 2025, sales of Filshie clips, applicators and accessories represented 26% of UTMD’s total U.S. Dollar denominated sales.” · word for word

Revenue concentration risk with PendoTECH OEM segment decline and China distributor cancellation.

“PendoTECH OEM sales dropped from $2.7M to $0.4M; China distributor order cancellation of $431K.”

Litigation risk from Filshie clip litigation in the US.

“Legal costs associated with the Filshie clip litigation in the U.S. were $783 lower in 2025.” · word for word

Embezzlement loss from Australia subsidiary.

“Recognition of a $195 loss from embezzled funds by UTMD’s Australia subsidiary manager.” · word for word

Tariff exposure

“Unfortunately, the U.S. government has recently set a 15% tariff on medical device imports from Ireland, which is a 'top-line' excise tax on intercompany sales to the U.S. from UTMD’s Ireland subsidiary, which substantially increases consolidated expenses without any impact on sales.” · word for word

Customer concentration

“UTMD’s 3Q 2025 financial performance was unusually affected by foreign trade events: i.e., the cancellation or possible delay of 'non-changeable/non-cancellable orders' by two outside the U.S. (OUS) distributors.” · word for word

Litigation expense

“Litigation expenses for Filshie product liability claims in the U.S. were lower in both 3Q and 9M 2025 compared to the same periods in 2024, but still significant at more than 3% of WW revenues.” · word for word

Foreign exchange risk

“Sales invoiced in foreign currencies represented 29% of total WW consolidated 3Q 2025 sales (when expressed in USD) and 30% of 9M 2025 total WW consolidated sales.” · word for word